Inflatable Penile Prosthesis
An inflatable penile prosthesis (IPP) offers patient-controlled rigidity for erectile dysfunction when other treatments are unsuitable or unsuccessful, or when an informed patient prefers definitive prosthetic treatment. It requires surgery, realistic expectations and the ability to operate the device. Trying every nonsurgical option is not an absolute prerequisite.[1]
This page covers devices, safety notices and interpretation of outcomes. For surgical selection, operative approaches, reservoir placement and salvage, use the Penile Implants atlas. Compare Malleable Penile Prosthesis when persistent firmness and simpler operation may better fit the patient's needs.
Components and Current Models
A three-piece implant contains paired corporal cylinders, a scrotal pump and a separate fluid reservoir. Inflation and deflation transfer fluid between these components. A two-piece design has fluid storage within the cylinders and therefore avoids a separate abdominal reservoir. Neither configuration eliminates infection, mechanical failure or revision.[2][3]
| Platform | Current device distinctions | Interpretation |
|---|---|---|
| AMS 700 — Boston Scientific | CX/CXR provide girth expansion; LGX adds length expansion. TENACIO and earlier MS pumps have distinct instructions. Specified components have rifampin/minocycline InhibiZone treatment. | Cylinder expansion is not a guarantee of restoring perceived penile length. Identify the actual pump and cylinder model. |
| Titan / Titan Prime — Coloplast | Bioflex cylinders and hydrophilic surface; pump/model variants differ. Titan Prime introduces the Press pump and revised components. | FDA approval and product availability are separate questions. Bench claims do not establish better long-term clinical outcomes. |
| Infla10 — Rigicon | X provides girth expansion; AX provides length and girth expansion. HydroShield hydrophilic coating includes components, connectors and rear-tip extenders. | It is not an uncoated device. The manufacturer's current page states that it is not available for sale in the US. |
| AMS Ambicor — Boston Scientific | Prefilled, preconnected two-piece device; fluid reservoirs are in the proximal cylinders. | It has no separate abdominal reservoir. Deflation involves bending the cylinders as taught for this model, not pressing a three-piece deflation button. |
Match the actual implant, supplied instructions and local authorization. There is no high-quality evidence establishing one brand as best for every patient. A small cadaver/bench rigidity comparison cannot predict clinical satisfaction, erosion or durability.[4][5][6][3][7]
Titan Prime: 2026 Approval and Availability
FDA approved supplement P000006/S072 on June 2, 2026. The linked Titan Prime GUDID record identifies the new model, while Coloplast's June announcement described a phased US launch beginning in late 2026. Confirm local access rather than assuming every approved configuration is already stocked. Manufacturer tubing-resistance and button-force findings are bench tests; long-term comparative patient outcomes are not yet established by that announcement.[8][5]
Device Safety Notices
AMS 700 with TENACIO: FDA Class II recall event 97603, initiated September 11, 2025, concerns specified devices with potential inflation/deflation problems from a nonconforming component. Check the exact catalog/UPN, UDI and lot in the linked records. Affected unused inventory should not be used and should be returned through the recall process. The notice states that no action is required for an implanted affected device that is functioning properly; inflation/deflation difficulties warrant evaluation. This is not a recall of every TENACIO implant or an instruction for routine explantation.[9]
An earlier Titan Touch recall, event 91800, concerns specified lots with a pump-wall thickness issue that could lead to premature failure. Its affected-inventory instructions also require exact model/lot matching. Consult the current record and manufacturer action notice rather than treating every Titan as affected.[10]
Selection and Counseling
Consider the patient's erectile goals, hand function, cognition, tissue quality and ability to obtain follow-up. A clinic demonstration can identify practical problems with the chosen pump. The Ambicor label still requires manual dexterity and strength; fewer components do not make it suitable for every patient unable to use a three-piece pump.[1][3]
Discuss irreversible corporal changes, perceived shortening, altered rigidity or sensation, persistent pain, infection, erosion and future surgery. An implant is not a lifetime device and does not restore libido, fertility or an absent orgasmic response. Avoid promises that urination, sensation or ejaculation can never be affected by surgery or complications.[2][3]
Active infection and device-specific material or medication hypersensitivity need review. AMS 700 InhibiZone components have additional contraindications including the listed antibiotic allergies and systemic lupus erythematosus. Optimize diabetes and other comorbidities, but do not present a single HbA1c value as a validated universal infection-safe threshold.[2][1]
Prior pelvic surgery or hernia mesh changes reservoir planning; it does not automatically prohibit a three-piece device. Ectopic placement may avoid a particular pelvic space but retains risks of injury, malposition, herniation and discomfort. Retrospective series and CT-distance measurements do not prove zero risk. See Reservoir Placement.[11][12]
Device Handling
- AMS 700 InhibiZone: the treated system can include cylinders, pump and reservoir. The TENACIO IFU prohibits soaking treated components; a brief rinse/dip is distinct from soaking. This is different from the AMS 800 AUS, whose PRB is not treated.
- Hydrophilic devices: follow the model's specified preparation. A surface that accepts a solution does not justify an arbitrary antibiotic mixture or transfer of another brand's instructions.
- Cycling: pump controls differ. Autoinflation and unintended deflation remain possible despite design features intended to reduce them.
- After implantation: intracavernosal injection therapy can damage the prosthesis and should not be continued. Preserve the device identification and component records.[2][6][3]
For patient teaching and troubleshooting, use Device Operation with the actual manufacturer's instructions.
Infection Prevention
Infection prevention combines patient assessment, skin preparation, antimicrobial selection, appropriate device handling and operative technique. No single coating or irrigation solution eliminates infection.
| Evidence | What it establishes | What it does not establish |
|---|---|---|
| Eid 2012, sequential single-surgeon experience | Seven infections among 1,511 coated/no-touch procedures (0.46%) in that cohort | A universal contemporary infection rate, or randomized separation of the coating and technique effects |
| Bole 2023, 1,071 procedures | Infection patterns changed after a practice stopped using 5% povidone-iodine irrigation | A randomized comparison proving one antibiotic irrigant best; “virulent organism” is not synonymous with Gram-negative or fungal infection |
| Chawareb 2025, 5,261 patients at 16 centers | 102 infections (1.9%); IV antifungal use was associated with lower adjusted infection odds (OR 0.22). Prolonged IV and postoperative oral antibiotics were not associated with protection | Causal proof that every candidate needs antifungal prophylaxis, or a universal antibiotic regimen |
These findings support careful review of local protocols and stewardship, with allergy, renal function, organism history and local susceptibility considered. Routine prolonged postoperative antibiotics lack convincing protective evidence. See the operative infection page for the procedure-specific discussion.[13][14][15][1]
Outcomes and Durability
Satisfaction and Function
Many recipients report substantial improvement, but response rates, questionnaires and follow-up affect the estimate. In Luna's cohort of 542 first implants, 322 answered the questionnaire and 109 attended clinical reassessment; the high reported quality-of-life result should be understood in that responding population. Subjective shortening and objective dimensions can differ. Observational satisfaction comparisons do not establish equivalent brands or promise a natural erection.[16][17]
Long-Term Survival
Miller's 2022 systematic review included 12 studies and 20,161 recipients. Estimated implant survival was 87.2% at five years, 76.8% at ten, 63.7% at fifteen and 52.9% at twenty years. These pooled estimates combine different implant eras and cohorts; they should not be turned into a promised 20-year lifespan for a current pump.[18]
The 2025 EAU-panel systematic review included 151 studies and 92,777 patients. Reported infection rates varied widely, with most studies below 5%; follow-up and study methods differed substantially. A heterogeneous range is not an individualized risk estimate, and mechanical failure accumulates over time.[19]
Reading Mechanical-Failure Reports
Studies consisting only of revised implants describe why failed devices were revised, not the probability that all implanted devices will fail. Griggs's 72-patient and Smelser's 68-patient revision cohorts cannot establish comparative brand lifespans from their component-failure proportions or median time among failures. New pain, loss of rigidity, difficulty cycling, erosion or infection requires assessment rather than assuming one familiar pump fault.[20][21]
Special Clinical Settings
Peyronie's disease: concomitant ED and residual deformity influence device selection and any additional straightening. Incision/grafting, modeling or other maneuvers have distinct risks; small technical series should not become a mandatory sequence. Use Prosthesis With Straightening.[22][23]
Ischemic priapism: delayed presentation and refractory ischemia may justify early prosthesis discussion. Evidence is predominantly retrospective, and EAU advises delaying implantation after a shunt to reduce infection and erosion. Device choice and timing depend on viable tissue, prior treatment and the patient's goals. See Priapism.[24]
After phalloplasty: the absence of native corporal support changes anchoring and complication risks. The 2026 international protocol is expert consensus. Ordinary ED infection, survival and satisfaction figures should not be transferred to a reconstructed neophallus.[25][26]
Combined AUS and IPP: selected series report favorable outcomes, but administrative data found more IPP reoperations after dual implantation. Small observational studies with different endpoints do not prove identical risk for simultaneous, staged and single-device surgery. Discuss both devices and the patient's priorities; see AUS device hub.[27][28]
MRI, Activation and Follow-up
These devices are MR Conditional, not universally MRI-safe. TENACIO, Ambicor, current Titan/Prime and older implants have different specified conditions. The field strength alone is insufficient: MRI staff must check the actual implant's gradient, RF, SAR and duration limits. Newer Titan conditions must not be transferred to Genesis or older models.[2][3][29]
Activation and intercourse depend on wound healing, comfort, device operation and the surgeon's instructions. The cited AMS labels describe initial cycling around 3–6 weeks and assessment for intercourse around 4–6 weeks; these are not universal schedules for complicated salvage or priapism. Arrange ongoing, usually annual, device review and earlier assessment for new pain, redness, drainage, urinary problems or impaired function.[2][3]
References
1. EAU. Sexual and Reproductive Health Guidelines, 2026: erectile dysfunction, penile prosthesis section. Guideline.
2. Boston Scientific. AMS 700 with TENACIO Pump — Instructions for Use, 51558342-01A. US English IFU. Accessed September 12, 2026.
3. Boston Scientific. AMS Ambicor Inflatable Penile Prosthesis — Directions for Use, 50654573-01C, English section. IFU. Accessed September 12, 2026.
4. Boston Scientific. AMS 700 Inflatable Penile Prosthesis, current model and ordering information. Manufacturer. Accessed September 12, 2026.
5. Coloplast. Titan Prime IPP: current product description and June 3, 2026 approval/launch announcement. Product; announcement.
6. Rigicon. Infla10 Inflatable Penile Prosthesis, current models and availability; Safety Information, INF10-07-03.2020. Manufacturer; safety document. Accessed September 12, 2026.
7. Wallen JJ, Barrera EV, Ge L, et al. Biomechanical Comparison of Inflatable Penile Implants: A Cadaveric Pilot Study. The Journal of Sexual Medicine. 2018;15(7):1034-1040. doi:10.1016/j.jsxm.2018.05.014
8. FDA. Titan Inflatable Penile Prosthesis, PMA supplement P000006/S072, approved June 2, 2026. Approval record; Titan Prime AccessGUDID record.
9. FDA. AMS 700 with TENACIO Pump, Class II recall event 97603, initiated September 11, 2025; affected models/lots and actions. All associated records; example record with action text. Accessed September 12, 2026.
10. FDA. Titan Inflatable Penile Prosthesis with Touch Pump, Class II recall event 91800, initiated March 1, 2023. Affected-device records; example action record. Accessed September 12, 2026.
11. Kavoussi M, Cook GS, Nordeck SM, et al. Distance From Critical Pelvic Structures: Radiographic Comparison of High Submuscular and Space of Retzius IPP Reservoir Placement Techniques. Urology. 2022;160:136-141. doi:10.1016/j.urology.2021.11.034
12. Baumgarten AS, Kavoussi M, VanDyke ME, et al. Avoiding Deep Pelvic Complications Using a 'Five-Step' Technique for High Submuscular Placement of Inflatable Penile Prosthesis Reservoirs. BJU International. 2020;126(4):457-463. doi:10.1111/bju.15106
13. Eid JF, Wilson SK, Cleves M, Salem EA. Coated Implants and "No Touch" Surgical Technique Decreases Risk of Infection in Inflatable Penile Prosthesis Implantation to 0.46%. Urology. 2012;79(6):1310-1315. doi:10.1016/j.urology.2011.11.076
14. Bole R, Habashy E, Yang D, et al. Timing and Causative Organisms Associated With Modern Inflatable Penile Prosthesis Infection. The Journal of Sexual Medicine. 2023;20(1):107-112. doi:10.1093/jsxmed/qdac001
15. Chawareb EA, Hammad MAM, Azad B, et al. Perioperative Antimicrobial Strategies in IPP Surgery: Associations Between Antifungals, Oral Antibiotics, and IV Antibiotic Duration, and Infection Outcomes. The Journal of Urology. 2025. doi:10.1097/JU.0000000000004716
16. Luna E, Rodriguez D, Barrios D, et al. Evaluation of Quality of Life After Inflatable Penile Implantation. The Journal of Sexual Medicine. 2022;19(9):1472-1478. doi:10.1016/j.jsxm.2022.06.018
17. Morgado A, Cavadas AS, Pacheco Figueiredo L, Tomada N. Long-Term Patient-Reported Satisfaction With Different Inflatable Penile Prosthesis: AMS 700CX vs Coloplast Titan. Revista Internacional de Andrologia. 2018;16(3):112-118. doi:10.1016/j.androl.2017.07.003
18. Miller LE, Khera M, Bhattacharyya S, et al. Long-Term Survival Rates of Inflatable Penile Prostheses: Systematic Review and Meta-Analysis. Urology. 2022;166:6-10. doi:10.1016/j.urology.2022.03.026
19. Cocci A, Capogrosso P, Minhas S, et al. Penile Prosthesis Implantation: A Systematic Review of Intraoperative and Postoperative Complications. International Journal of Impotence Research. 2026;38:93–122 (online June 2025). doi:10.1038/s41443-025-01108-4
20. Griggs R, Henry G, Vasylieva V, Karpman E. Mechanical Failure of Inflatable Penile Prostheses: Time to Failure and Reasons for Replacement. The Journal of Sexual Medicine. 2025;22(5):909-915. doi:10.1093/jsxmed/qdaf053
21. Smelser AM, VanDyke ME, Nealon SW, et al. Mechanical Indications for Inflatable Penile Prosthesis Revision. The Journal of Sexual Medicine. 2023;20(7):1044-1051. doi:10.1093/jsxmed/qdad064
22. Hammad MAM, Barham DW, Simhan J, et al. A Multicenter Evaluation of Penile Curvature Correction in Men With Peyronie's Disease Undergoing Inflatable Penile Prosthesis Placement. The Journal of Sexual Medicine. 2025;22(2):349-355. doi:10.1093/jsxmed/qdae192
23. Berookhim BM, Karpman E, Carrion R. Adjuvant Maneuvers for Residual Curvature Correction During Penile Prosthesis Implantation in Men With Peyronie's Disease. The Journal of Sexual Medicine. 2015;12 Suppl 7:449-454. doi:10.1111/jsm.13001
24. EAU. Sexual and Reproductive Health Guidelines, 2026: priapism, immediate penile prosthesis and recommendations sections. Guideline.
25. Levy M, Falcone M, Bohr J, et al. Penile Implants After Phalloplasty in Transgender Individuals: A Consensus-Based Surgical Clinical Protocol. The Journal of Sexual Medicine. 2026;23(2):qdaf365. doi:10.1093/jsxmed/qdaf365
26. Rooker SA, Vyas KS, DiFilippo EC, et al. The Rise of the Neophallus: A Systematic Review of Penile Prosthetic Outcomes and Complications in Gender-Affirming Surgery. The Journal of Sexual Medicine. 2019;16(5):661-672. doi:10.1016/j.jsxm.2019.03.009
27. Ammirati E, Polisini G, Giammò A. Surgical Treatment Options and Outcomes for Concomitant Treatment of Post-Prostatectomy Erectile Dysfunction and Male Stress Urinary Incontinence. International Journal of Impotence Research. 2026;38(3):193-205. doi:10.1038/s41443-025-01202-7
28. Patel N, Golan R, Halpern JA, et al. A Contemporary Analysis of Dual Inflatable Penile Prosthesis and Artificial Urinary Sphincter Outcomes. The Journal of Urology. 2019;201(1):141-146. doi:10.1016/j.juro.2018.07.046
29. Coloplast. MRI Compatibility and Latex Content: Penile Prostheses, August 2026. Manufacturer MRI conditions.